A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China....

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Liya, Liang, Bin, Hu, Huixian, Yang, Wenli, Lin, Shengyun, Cao, Lihong, Li, Kongfei, Kuang, Yuemin, Shou, Lihong, Jin, Weimei, Lan, Jianping, Ye, Xingnong, Le, Jing, Lei, Huyi, Fu, Jiaping, Lin, Ying, Jiang, Wenhua, Zheng, Zhiying, Jiang, Songfu, Fu, Lijuan, Su, Chuanyong, Yin, XiuFeng, Liu, Lixia, Qin, Jiayue, Jin, Jie, Qian, Shenxian, Ouyang, Guifang, Tong, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271788/
https://www.ncbi.nlm.nih.gov/pubmed/35832562
http://dx.doi.org/10.3389/fonc.2022.905490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271788/
https://www.ncbi.nlm.nih.gov/pubmed/35832562
http://dx.doi.org/10.3389/fonc.2022.905490

Ejemplares similares